Discovery of a Defective SIGIRR-dependent Anti-inflammatory Pathway in Cystic Fibrosis
Researchers discovered that a defective isoform of the SIGIRR gene activates an inflammatory pathway associated with cystic fibrosis
Cystic fibrosis (CF) is a life-threatening genetic disorder, marked by recurrent infections resulting in chronic lung inflammation. Unfortunately, the mechanisms underlying this inflammation are not fully elucidated. In this study, researchers from Japan found that a defect in the single immunoglobulin interleukin-1 receptor (IL-1R)-related molecule (SIGIRR) gene led to the suppression of an anti-inflammatory pathway in the lung epithelial cells of patients with CF. This finding can support the development of novel drugs against this disease.
Cystic fibrosis (CF) is an inherited lung disease, marked by chronic and excessive lung inflammation, mucus retention, and airway obstruction owing to recurrent bacterial and viral infections. It is highly prevalent in the European and North American populations.
Although it is known that an increased production of interleukin-8 (IL-8)—a type of cytokine, and defects in the causative gene causes hyperinflammation associated with CF, evidence suggests that certain dysregulated genes also play a key role in the mechanism underlying this inflammation.
One such set of genes are toll-like receptors (TLRs), which cause inflammation in airway epithelial cells in response to pathogen associated molecular patterns (PAMPs)—immune signals alerting the cells of an infection. In many inflammatory diseases, pathways that negatively regulate TLRs, i.e., prevent them from causing an inflammatory effect, are dysregulated.
However, little is known regarding the negative regulators of TLRs which lead to inflammation in case of CF.
To address this gap, a research team led by Associate Professor Tsuyoshi Shuto from Graduate School of Pharmaceutical Sciences at Kumamoto University, Japan and Lecturer Keiko Shuto from the Faculty of Pharmaceutical Sciences at Sojo University, Japan conducted a study to investigate the mechanisms underlying CF, by studying a membrane protein known as single immunoglobulin interleukin-1 receptor (IL-1R)-related molecule (SIGIRR). SIGIRR is known to cause inflammation by disrupting inflammatory regulation in viral infections and is a negative regulator of TLRs.
In their study, which was published in Volume 23, Issue 14 of International Journal of Molecular Sciences on July 13, 2022, the team used a range of molecular techniques to conduct experiments on lung epithelial cells of patients with CF, and non-CF cells.
Their findings suggested that the cell surface expression of SIGIRR was much lower in CF epithelial cells as compared to that of non-CF epithelial cells. To their surprise, they also observed high expression of an alternate, spliced isoform of SIGIRR termed as ∆8-SIGIRR, in CF lung epithelial cells.
“We discovered that ∆8-SIGIRR is formed due to dysfunctional mRNA splicing, which leads to the loss of a DNA segment known as exon-8 from the full-length SIGIRR, known as WT-SIGIRR,” remarks Prof. Shuto while discussing this unique finding.
On further analysis, the team found that the increased expression of ∆8-SIGIRR on the cell membrane of CF lung epithelial cells decreases the expression and function of WT-SIGIRR, indicative of its dominant-negative effect. Due to this diminished expression, WT-SIGIRR is unable to activate IL-37b—an anti-inflammatory molecule which inhibits TLRs, resulting in severe inflammation associated with CF.
This defect in the IL37-SIGIRR signal leading to persistent activation of inflammatory TLRs is a novel and exciting discovery into the mechanisms underlying CF-associated inflammation.
So, what are the implications of these findings in the long run? “Our findings will lead to a deeper understanding of the pathological function of ∆8-SIGIRR in CF. Naturally, this will pave the way for the development of novel SIGIRR-targeting drugs for previously unknown targets of CF-associated inflammation,” says Prof. Shuto.
Here’s hoping that this discovery leads to the development of new and effective drugs and provide much-needed relief to patients with CF!
About Associate Professor Tsuyoshi Shuto
Dr. Tsuyoshi Shuto received his PhD in 2006 in Kumamoto University, Japan, where he currently works as an Associate Professor at the Graduate School of Pharmaceutical Sciences. His research interests lie broadly in the fields of cell biology, genetics, immunology, histology, molecular biology, and neuroscience. Recently, his research has focused on lung diseases such as chronic obstructive pulmonary disease, cystic fibrosis, and more. He has published more than 75 papers in reputed international journals, which have cited by researchers across the globe.
[Funding]
- Japan Society for the Promotion Science (JSPS) KAKENHI (JP25460102, JP17H03570, JP15J09420
- JSPS Program on Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (S2510)
- MEXT - The Program for Leading Graduate Schools HIGO (Health life science: Interdisciplinary and Global Oriented